Retatrutide pricing: why there is no official price yet
Retatrutide has no official price. No regulator has approved it, and Eli Lilly's second-quarter 2026 earnings release, dated August 5, 2026, says the company plans to submit a Biologics License Application to the FDA in the first quarter of 2027. With no approval there is no pharmacy price, no insurance price and no manufacturer list price. Every price you find online belongs to something else, and this article sorts out what that something is.
Is there an official retatrutide price?
No. Lilly's release says its clinical data package for retatrutide is complete to support global registrations, and none of the sources we opened, checked on October 8, 2026, report an approval in any country. A launch price will be set by the manufacturer after a regulator approves the drug, and none of the sources we opened give one. Any figure quoted today as the future price is a guess, so we do not print one.
The trial record explains why people are asking. The phase 2 trial in the New England Journal of Medicine reported a mean weight change of -24.2% at 48 weeks in its highest arm, and the sponsor-reported TRIUMPH-1 phase 3 trial reported -28.3% at 80 weeks. Both come with side-effect signals, which our retatrutide trial results article walks through. Strong trial numbers do not create a product anyone can legally dispense yet.
Can a doctor prescribe it, or a pharmacy compound it?
Not as an approved medicine, because none exists. A compounding route is also closed: the FDA's page on unapproved GLP-1 drugs, current as of October 1, 2026, states that retatrutide and cagrilintide cannot be used in compounding under federal law. Some storefronts in search results describe compounded retatrutide as an option. The FDA's statement says otherwise.
What do research-use listings cost?
Some chemical suppliers list retatrutide labeled for laboratory research. One we track, American Peptides, listed five vial sizes when we checked on October 8, 2026, and every size was in stock. Core Power Peptides, our other supplier partner, did not list retatrutide at its last check.
| Vial size | Listed price | Price per mg |
|---|---|---|
| 10 mg | $105 | $10.50 |
| 20 mg | $200 | $10.00 |
| 30 mg | $240 | $8.00 |
| 48 mg | $300 | $6.25 |
| 60 mg | $400 | $6.67 |
The per-milligram rate falls as vials get bigger until 48 mg, then rises again at 60 mg, so the biggest vial is not the cheapest by weight. This is one supplier's price list, not a market average, and we have not surveyed other sellers. We earn a commission on links to this supplier, as the disclosure on each price card says. The same listing sits on our retatrutide profile.
Why the lowest price per milligram tells you little
A price per milligram assumes the vial contains the right molecule, at the stated purity, in the stated amount, free of contaminants. The price itself checks none of those. The supplier states 99% or higher purity by HPLC and a lot-matched certificate of analysis for every batch. Those are the supplier's claims, and we have not reviewed a retatrutide certificate from it.
| Assumption behind the price | What tests it | Where it shows up |
|---|---|---|
| It is retatrutide | Mass spectrometry identity result | Certificate of analysis |
| It is the purity claimed | HPLC purity result | Certificate of analysis |
| The vial holds the labeled amount | A content assay | Often missing from certificates |
| It is free of bacterial toxins | Endotoxin and sterility tests | Only on some certificates |
| A named outside lab did the work | Lab name, date and lot number | Certificate header |
Our guide to reading a certificate of analysis explains each row. The FDA's page lists the failures it has seen in unapproved GLP-1 products: contamination, storage problems during shipping, counterfeit products, and vials with the wrong amount of active ingredient or none.
What does the FDA say about research-labeled retatrutide?
The FDA states that it has warned companies selling unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that were falsely labeled for research or as not for human consumption, yet sold directly to consumers for human use with dosing instructions. The agency calls such products of unknown quality that may be harmful. The label "research use only" means laboratory work. It does not describe a lower-priced version of a medicine, and this site gives no instructions for using any compound on a person.
What about approved options?
Approved prescription medicines for weight management already exist, including semaglutide and tirzepatide, and a physician is the right person to discuss them. Tirzepatide's pivotal trial, SURMOUNT-1, reported -20.9% at 72 weeks in its highest arm. Our head-to-head comparison covers how those two approved drugs compare. Research-grade material is not the approved product, so its price cannot be compared with a pharmacy price. For the longer version of that point, see research-grade versus prescription GLP-1.
Quick answers
- Is retatrutide available at a pharmacy? No. It is not approved, and the FDA says it cannot be compounded.
- How much will it cost once approved? Unknown. Lilly has not announced a price, and its first filing is planned for Q1 2027.
- Will insurance cover it? There is nothing to cover until a regulator approves it.
- Why do so many sites show prices? They are listing research-use-only material, which is a different product from a future approved drug.
- What should a buyer of research material check first? A lot-specific certificate from a named outside lab, including identity and purity results.
Bottom line
Retatrutide has no official price until a regulator approves it, and Lilly's own timeline puts the first filing in the first quarter of 2027. The prices that exist today are for research-use-only listings, and a price per milligram says nothing about identity, purity or amount. Track the regulatory status on our retatrutide profile, and read the certificate guide before trusting any listing.
Compounds in this post
GIP / GLP-1 / Glucagon Triple Agonist
Not currently stocked by Core Power Peptides.
From $105 (10 mg) at American Peptides
GIP / GLP-1 Dual Agonist
$320 · 50 mg vial · $6.40/mg at Core Power Peptides (checked Sep 29, 2026)
From $100 (10mg) at American Peptides
GLP-1 Receptor Agonist
$75 · 10 mg vial · $7.50/mg at Core Power Peptides (checked Sep 29, 2026)
From $90 (10 mg) at American Peptides
Disclosure: this is a paid affiliate relationship. Links marked “Shop”, “Check price” or “View” go to Core Power Peptides or American Peptides, our research-peptide supplier partners. We may earn a commission when you purchase through these links, at no added cost to you. This never changes which compounds we cover or how we describe them. Products are sold for laboratory research only, not for human or veterinary use.
Sources
- Lilly reports second-quarter 2026 financial results (Form 8-K exhibit) (U.S. Securities and Exchange Commission)
- FDA's concerns with unapproved GLP-1 drugs used for weight loss (U.S. Food and Drug Administration)
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial (New England Journal of Medicine)
- Retatrutide TRIUMPH-1 phase 3 weight-loss endpoints (HCPLive)
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) (New England Journal of Medicine)
Keep reading
Reviewed by the Peptides For Weight Loss editorial team. Research use only; nothing here is medical advice. See our editorial standards.